Interpace Biosciences Announces Results of Seminal Clinical Validation Study for Thyroid Assays
October 26, 2020 06:30 ET
|
Interpace Biosciences, Inc.
Study Demonstrates Superior Performance of ThyGeNEXT® and ThyraMIR® vs. Other Molecular Tests PARSIPPANY, NJ, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG)...
Interpace Diagnostics Announces Contract with BCBS of Massachusetts
March 10, 2020 06:55 ET
|
Interpace Biosciences, Inc.
In-Network Access for More Than 3 Million Members Parsippany, NJ, March 10, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced...
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
December 17, 2019 06:55 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage...
Interpace Diagnostics Announces Presentation at the World Congress on Thyroid Cancer
June 13, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Rome, ITALY, June 13, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced that...
Interpace Diagnostics Announces Publication of Important New Data on Thyroid Test Performance
May 01, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Data from Registry Study Confirms the Value of ThyGenX® and ThyraMIR® in a Clinical Setting PARSIPPANY, NJ, May 01, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc....
Interpace Diagnostics to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Tuesday, November 13, 2018
November 06, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it will report its third quarter 2018 financial results after the close of...
Interpace Diagnostics Presents Favorable New Data at the 88th Annual Meeting of the American Thyroid Association (ATA)
October 15, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
ThyGenX® and ThyraMIR® Data from Clinical Experience Study Shows Positive Results PARSIPPANY, NJ, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced that...
INTERPACE DIAGNOSTICS ANNOUNCES PARTICIPATION AT THE 20TH ANNUAL GLOBAL INVESTMENT CONFERENCE SPONSORED BY H.C.WAINWRIGHT & CO.
August 27, 2018 08:30 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that...